Is it sufficient to maintain patients with atrial fibrillation and established PAD on a DOAC or VKA alone, or is there an additional benefit to adding an antiplatelet agent for CVD benefit?

Topics: Cardiology • Peripheral Vascular Disease • Preventive Cardiology • Atrial Fibrillation

If so, would you prefer a P2Y12i over low-dose aspirin?

Answer from: at Academic Institution

If they have medically managed PAD with no recent intervention/revascularization, anticoagulation alone should be sufficient especially if their bleeding risk is not low. In general, most patients on anticoagulation for AF do not need to also be on anti-platelet agents for secondary preventio...

Comments

at Corewell Health Medical Center
Are most providers stopping antiplatelet therapy i...

at Yale University School of Medicine
I would generally continue anti-platelet Rx for 12...

Related Questions